Thomas Wellner

Thomas Gordon Wellner currently works at Brighton Asset Management LLC, as Chief Executive Officer, Cytophage Technologies Ltd., as Chairman from 2025, Ontario Association of Medical Laboratories, as Director, Signature Senior Lifestyle Holdings Ltd., as Director, Signature Senior Lifestyle Finance Ltd., as Director from 2018, Life Sciences Ontario, as Director, Signature Senior Lifestyle Ltd., as Director from 2018, Cipher Pharmaceuticals US LLC, as Director, WR Midco Ltd., as Director from 2016, SSL Group (UK) Ltd., as Director, Signature Senior Lifestyle Operations Ltd., as Director from 2018, Signature Lessee Ltd., as Director from 2018, WR Operations 3 Ltd., as Director from 2018, WR Operations 2 Ltd., as Director from 2018, Signature Senior Lifestyle Investments II Ltd., as Director from 2018, Andlauer Healthcare Group, Inc., as Independent Director from 2019, Ontario Teachers Pension Plan, as Director, Rothesay Netherwood School, as Member-Governors Board from 2011, and Wellcap Advisors Ltd., as President.
Mr. Wellner also formerly worked at Therapure Biopharma, Inc., as President & Chief Executive Officer from 2008 to 2011, CML HealthCare, Inc., as President & Chief Executive Officer from 2012 to 2013, LifeLabs, Inc., as Co-Chief Executive Officer, Royal City Manor Ltd., as President & Chief Executive Officer, Revera, Inc. (Canada), as President, Chief Executive Officer & Director from 2014 to 2023, Atlantic Healthcare Plc, as Non-Executive Chairman from 2017 to 2020, Cipher Pharmaceuticals, Inc., as Independent Director from 2014 to 2017, Novadaq Technologies, Inc., as Independent Director, DiaMedica Therapeutics, Inc., as Director from 2008 to 2012, Cotinga Pharmaceuticals, Inc., as Independent Director from 2012 to 2013, 2ndsite, Inc., as Director, Eli Lilly & Co., as President & General Manager, and Lilly Deutschland GmbH, as President.
Mr. Wellner received his undergraduate degree from Queen's University.